Podcasts about mbbs

Activity Objectives:Compare the nature of genomic alterations that define clinically important subsets of acute lymphoblastic leukemia.Give examples of how genomic insights inform risk stratification and management of acute lymphoblastic leukemia.Claim CME Credit Here!

Please visit answersincme.com/860/cvdprostate-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Cookson, MD; Alicia Morgans, MD, MPH; and Avirup Guha, MD, MBBS, MPH, FAHA, FACC, FESC, FICOS. In this activity, experts in prostate cancer discuss cardiovascular risk in patients receiving androgen-deprivation therapy (ADT). Upon completion of this activity, participants should be better able to: Evaluate the impacts of prostate cancer and ADT on cardiovascular risk; Translate the latest research for cardiovascular management of patients on ADT to clinical practice; and Design personalized treatment approaches to optimize ADT across treatment settings.

In today's episode, we spoke with Raji Shameem, MD, and Shubham Pant, MD, MBBS. Dr Shameem is a clinical assistant professor of medicine at the Orlando College of Osteopathic Medicine, an assistant professor of Medicine at the University of Central Florida, and a physician at Orlando Health. Dr Pant is a professor in the Department of Gastrointestinal Medical Oncology and the Department of Investigational Cancer Therapeutics, as well as the director of Clinical Research at The Sheikh Zayed Center For Pancreatic Cancer Research at The University of Texas MD Anderson Cancer Center in Houston.In our exclusive interview, Drs Shameem and Pant discussed the rapidly evolving pancreatic cancer treatment paradigm, going in-depth on topics like the role of liposomal irinotecan (Onivyde), the FDA approval of daraxonrasib (Rasonque) for patients with metastatic disease, and novel treatments that are in development. The 2 experts also covered which directions they see the pancreatic cancer field moving towards in the future.

In this episode of The Lead, host Deep Chandh Raja, MBBS, MD, PhD, FHRS, is joined by Kars Neven, MD, PhD, and David Chieng, MBBS, CCDS, to discuss the journal article, Radiofrequency Ablation Produces Stiffer Atrial Lesions Than Pulse Field Ablation: In vivo and ex vivo magnetic resonance elastography in pigs. Together, they discuss the study's comparison of atrial lesions produced by radiofrequency ablation and pulse field ablation using in vivo and ex vivo magnetic resonance elastography in pigs. Learning Objectives Review the study's comparison of atrial lesions produced by radiofrequency ablation and pulse field ablation. Discuss the use of in vivo and ex vivo magnetic resonance elastography to evaluate atrial lesions in pigs. Examine the differences in atrial lesion stiffness observed following radiofrequency and pulse field ablation. Host: Deep Chandh Raja, MBBS, MD, PhD, FHRS Guests: Kars Neven, MD, PhD and David Chieng, MBBS, CCDS Disclosures: D. Raja No relevant disclosures K. Neven Honoraria/Speaking/Consulting Fee: Boston Scientific, Biosense Webster, Inc., Lifetech Scientific Stock Options-Privately Held: Field Medical D. Chieng No relevant disclosures

My guest today is Dr. Kishore Reddy, co-founder of & Chief Strategy Officer at ProHance.Conversation highlights:Background & Early Life:Kishore grew up across India—moving from Gujarat to Delhi and eventually settling in Bangalore, which he considers his home.Medical Career & Transition to IT:Completed his MBBS from Bangalore Medical College with plans to pursue neurology residency in the US, inspired by family members.After facing US visa denials (under section 214B), his brother Kiran suggested exploring the booming IT field around 1998–1999.Approached Sudhir Sharma at Network Solutions to learn IT on the job without demanding a salary.Leveraged his medical background's intensive reading habits to quickly master IT manuals.Early IT Experience & Growth:Had early exposure to computers during childhood thanks to his father and brother, including learning GW-BASIC.Worked on a World Bank-funded Health Information System (HIS) / Hospital Management Information System (HMIS) project for the Government of Karnataka.Mentored by DVN Sarma, gaining early exposure to data analytics and statistics.Network Solutions was acquired by IBM in 2005, leading to Kishore working at IBM for four and a half years.Founding Jamocha Tech:Decided to start his own venture in October 2008 and teamed up with Rajesh (his former colleague from Network Solutions).Received early mentorship and backing from Sudhir Sharma.Named the company Jammocha Tech over coffee at Barista, driven by their passion for Java technology.Evolution to ProHance:Initially built multiple products (e.g., network management, energy management) before streamlining focus.Shifted roles based on advice: Kishore transitioned to sales/technology head, while Rajesh handled delivery and support.Coined the name ProHance from "Productivity Enhancement" ("Pro" + "Hance").Rebranded completely to Prohands to avoid market confusion between the company and product names.Formally established ProHance India Private Limited in 2020, with ChrysCapital taking a majority stake in 2023.Key Entrepreneurial Takeaways:Adaptability: Expect the journey not to be a straight line and remain flexible.Team Building: Recognize that while founders start the journey, the team drives the company's ultimate success.Brand Focus: Avoid confusing customers with too many entity/product names; stick to one strong identity.https://www.linkedin.com/in/kishore-r-2a37aa5/Experienced Chief Technology Officer with a demonstrated history of working in the information technology and services industry. Strong product engineering skills. Built and rolled out several large enterprise class products across various domains. 

Description: In this episode of The Lead, host Jenelle Dziano, PhD candidate, is joined by Roopinder Sandu, MD, MPH, FHRS and Louise Segan, MBBS, MPH, PhD to discuss the journal article, Weight Loss in Older Patients With Persistent Atrial Fibrillation, The LOSE-AF Randomized Clinical Trial. Together, they review the findings of the LOSE-AF randomized clinical trial examining weight loss in older patients with persistent atrial fibrillation. Learning Objectives Review the key findings of the LOSE-AF randomized clinical trial examining weight loss in older patients with persistent atrial fibrillation. Discuss the role of weight loss in the management of older patients with persistent atrial fibrillation. Examine the clinical implications of the study findings for patients with persistent atrial fibrillation. Host: Jenelle Dziano, PhD candidate   Guests: Roopinder Sandu, MD, MPH, FHRS and Louise Segan, MBBS, MPH, PhD   Disclosures: J. Dziano No relevant disclosures R. Sandu No relevant disclosures L. Segan No relevant disclosures

Interview with Tolani Ajagbe, MBBS

In conclusion to this special episode hosted by the AOFAS Young Physicians Committee and EFAS Youth Committee, AOFAS surgeons Matt Conti, MD, and Sara Galli, MD, join EFAS surgeons Amit Patel, MBBS, BSc, MSc FRCS, and Tom Lewis, MBChB, BSc, MFSTEd, FRCS, PhD, to discuss Hallux Rigidus treatment options.  For additional educational resources, visit AOFAS.org

This episode features Dr. Mingyang Song ScD from Harvard University (USA), speaking about epidemiological evidence connecting the gut microbiota to colorectal cancer (CRC) and whether the evidence supports the gut microbiota as a ‘driver' or a ‘passenger. Dr. Song explains how he and colleagues studied the gut microbiome in a subset of people from the Nurses' Health Study. It's known that adenoma removal reduces CRC risk, but doesn't eliminate it. Does the gut microbiome contribute to this remaining risk? The researchers found that many years after adenoma removal, individuals had a different gut microbiota compared with healthy controls, indicating that the microbiome profile is not fully restored by adenoma removal. People with past adenoma removal had a gut microbiota that overlapped with that of current CRC patients, with the caveat that lots of heterogeneity was observed. Diet and lifestyle also correlate with both CRC development and gut microbiome composition, with some of the main factors reducing CRC risk being dietary fiber, fruits, vegetables, whole grains, and calcium. These and other healthy lifestyle factors were associated with fewer of the gut microbial members typically seen in CRC. Next, prospective studies are needed to determine whether gut microbiota changes truly precede CRC and independently contribute to risk. This line of research could also lead to a more tailored approach to CRC screening, with risk factors being taken into account. Episode abbreviations and links: Study on a subset of participants in the Nurses' Health Study, showing those who previously experienced adenoma removal had gut microbial similarities to CRC: Long-lasting gut microbiome and fecal metabolome alterations after colorectal adenoma removal and their relationship to colorectal cancer About Dr. Mingyang Song ScD: Mingyang Song, MBBS, ScD is Associate Professor of Clinical Epidemiology and Nutrition and Faculty Director of Graduate Studies in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health, and Associate Professor of Medicine at Harvard Medical School. His research focuses on two complementary areas: (1) integrating large-scale prospective cohort studies with biomarker-driven clinical trials to develop nutrition- and microbiome-based approaches for cancer prevention and treatment; and (2) combining electronic health records with molecular and spatial profiling to enable precision risk prediction and personalized colonoscopy screening and surveillance. Dr. Song has received numerous honors, including the NextGen Star Award from the American Association for Cancer Research (AACR) and the Young Investigator Award from the American Gastroenterological Association (AGA). He currently serves as the Vice Chair of the Obesity, Metabolism and Nutrition (OMN) Section at AGA, Statistics Associate Editor of Gut, Associate Editor of the Journal of the National Cancer Institute (JNCI), and Editor of the European Journal of Epidemiology.

The radiologist shortage is real, and international medical graduates (IMGs) are already helping solve it. Sohrab Afshari Mirak, MD, speaks with cohosts Surbhi Raichandani, MD, and Sherry Wang, MBBS, about his path from Tehran to UCLA, the American Board of Radiology Alternate Pathway, visa hurdles, and what IMGs bring to patient care. Listen to their discussion in episode 3 of Difficult Conversations, an AJR Podcast Series. *Key Takeaways Beyond the Step Score: Residency programs should not filter IMG applicants based on USMLE scores or graduation gaps; letters of recommendation and other application components offer additional important information.   The ABR Alternate Pathway: Recent changes by the American Board of Radiology now allow internationally trained radiologists to complete their four required fellowship years non-consecutively within an eight-year window, significantly reducing a source of uncertainty.    Clinical Diversity: IMGs bring unique proficiencies and skill sets developed in healthcare systems with workflows that differ from in the United States. *Chapters 0:00 - Welcome and Intro 0:54 - Impact of Radiologist Shortage 3:43 - Dr. Mirak's IMG Journey 6:07 - Residency Screening Pitfalls 10:02 - Letters and Observerships 12:14 - Research and Networking Tips 15:21 - ABR Alternate Pathway 18:52 - Visa Choices and Waivers 25:44 - Cultural Support for IMGs 28:38 - Global Models and IMG Value 35:56 - One Policy Change  38:05 - Closing Thoughts Follow AJR on Social Media LinkedIn: https://www.linkedin.com/showcase/ajr-radiology/ YouTube: https://www.youtube.com/channel/UCfFAYezkLMxJGMgIJLN0Dpg Instagram: https://www.instagram.com/ajr_radiology/ TikTok: https://www.tiktok.com/@ajr_radiology X: https://x.com/AJR_Radiology BlueSky: https://bsky.app/profile/ajrradiology.bsky.social

Neda Nikpoor, MD, and Neda Shamie, MD, are joined by Radhika Rampat, MBBS, BSc(Hons), FRCOphth, for an exploration of sustainability in ophthalmology. They discuss the AECOS Green Working Group, waste reduction, and how to champion sustainability locally. 

Please visit answersincme.com/ZGK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Amer Zeidan, MBBS, MHS. In this activity, an expert in myelodysplastic syndromes (MDS) discusses approaches to optimize management of anemia in lower-risk MDS. Upon completion of this activity, participants should be better able to: Translate the latest clinical trial data to the management of patients with lower-risk MDS; Evaluate evidence-based strategies for optimizing the use of available agents in lower-risk MDS; and Design treatment plans that effectively sequence available therapies in patients with lower-risk MDS.

In this special episode hosted by the AOFAS Young Physicians Committee and EFAS Youth Committee, AOFAS surgeons Matt Conti, MD, and Sara Galli, MD, join EFAS surgeons Amit Patel, MBBS, BSc, MSc FRCS, and Tom Lewis, MBChB, BSc, MFSTEd, FRCS, PhD, to discuss Hallux Rigidus treatment options. Stay tuned for the conclusion of this 2-part series.   For additional educational resources, visit AOFAS.org

Join hosts Nidhi Madan, MD; Prashant Nagpal, MD, FSCCT; Jill Jacobs, MD, MS-HQSM, FSCCT and Cristina Fuss, MD, PhD, FSCCT as they take a deep dive into featured articles in the May – June 2026 issue of the Journal of Cardiovascular Computed Tomography (JCCT). Our hosts chat with Yipu Ding, MD and Tom Semple, MDres, FRCR, MBBS, BSc.Matching the protocol to the clinical question in pediatric coronary CT - one size doesn't have to fit all Importance of Coronary Artery Lumen Size in the Relationship Between Coronary Artery Plaque and Vessel-Specific Ischemia: A Post Hoc Analysis of CREDENCE and PACIFIC-1Support the show

How fast can a knee MRI examination be performed? Zahra F. Rahmatullah, MBBS, discussed the article by Leonhardt et al. exploring a deep-learning pipeline for achieving 7-minute knee MRI. Full article: Arthroscopy-Validated Diagnostic Performance of a Deep Learning Reconstruction Pipeline for Rapid 7-Minute Five-Sequence 3-T Knee MRI Follow AJR on Social Media LinkedIn: https://www.linkedin.com/showcase/ajr-radiology/ YouTube: https://www.youtube.com/channel/UCfFAYezkLMxJGMgIJLN0Dpg Instagram: https://www.instagram.com/ajr_radiology/ TikTok: https://www.tiktok.com/@ajr_radiology X: https://x.com/AJR_Radiology BlueSky: https://bsky.app/profile/ajrradiology.bsky.social

In this episode of The Lead recorded at HRS2026, host Danesh Kella, MBBS, FHRS is joined by Jeffrey S. Healey, MD, FHRS and Fred M. Kusumoto, MD, FHRS to discuss the journal article, Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (The CLOSURE-AF Trial). Together, they review the study findings comparing left atrial appendage closure with medical therapy in patients with atrial fibrillation and discuss the potential implications for clinical practice. Learning Objectives Review the design and key findings of the CLOSURE-AF Trial comparing left atrial appendage closure with medical therapy in patients with atrial fibrillation. Discuss the comparative considerations of left atrial appendage closure and medical therapy for the management of atrial fibrillation. Examine the potential clinical implications of the CLOSURE-AF Trial for treatment decision-making in patients with atrial fibrillation.   Host: Danesh Kella, MBBS, FHRS Guests: Jeffrey S. Healey, MD, FHRS and Fred M. Kusumoto, MD, FHRS   Disclosures: D. Kella Honoraria/Speaking/Consulting Fee: Zoll Medical Corporation, MBW Spectrum   J. Healey Honoraria/Speaking/Consulting Fee: Boston Scientific, Servier Research: Pfizer, Boston Scientific, Medtronic, Inc. Speakers' Bureau: Bristol-Myers Squibb   F. Kusumoto No relevant disclosures

In this episode, JHLT: The Podcast explores the study "The ASSIST CLAD study: A phase 2 randomized controlled trial of mesenchymal stromal cells for new-onset chronic lung allograft dysfunction," which appears in the August print issue of JHLT. Today's guest is Daniel C. Chambers, MBBS, MD, of The Prince Charles Hospital and Queensland Lung Transplant Service in Brisbane, Australia. From across the dateline, he and Digital Media Editor Erika Lease discuss: What inspired the team to explore the use of mesenchymal stromal cell (MSC) infusions in CLAD patients Preparation and treatment considerations for using MSCs How despite the negative outcome—the MSCs made no clear improvements in the patient groups—the study still pushes the field forward For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this episode, you'll discover:Has India really delivered on the 2014 promise? The BJP's case for poverty reduction, infrastructure, digital payments and welfare, and the opposition's counter using unemployment, savings and rural wage data.Why India's demographic dividend could become a demographic disaster if the country doesn't create enough productive jobs before the population starts ageing.The uncomfortable education problem: More IITs, AIIMS, MBBS seats and higher-education enrolment, but are Indian students actually becoming employable?Why paper leaks and police brutality expose a bigger question: Is the government reacting quickly enough, or should a government of 12 years have built systems that prevent these failures altogether?The manufacturing paradox: India has attracted investment, expanded infrastructure and entered sectors like semiconductors, so why hasn't manufacturing's share of GDP reached the target set in 2014?Can India really de-risk itself from global shocks? From the Russia-Ukraine war to Middle East disruptions, how vulnerable is India's growth model to events outside its control?The biggest debate of all: When two sides can produce a statistic to counter almost every statistic, how do we actually measure whether a country is progressing?This isn't a debate about whether the BJP has done everything right or everything wrong.It's a debate about a much harder question:After 12 years in power, what should India's benchmark for success actually be?Watch the full debate and decide for yourself who made the stronger case for India's future.Chapters -Evaluating the BJP governance record after 12 years in power. Understand the current political climate and actual performance metrics.This video provides a critical look at the long-term impact of 12 years of BJP leadership in India. If you are following Indian political analysis, this breakdown examines whether the ruling party is still in its honeymoon phase or if it has entered a new stage of governance maturity.We assess the trajectory of the current administration by moving beyond standard narratives. By focusing on the 12 years of BJP tenure, we clarify the shift from initial promises to current government performance. This session is designed for anyone seeking an objective perspective on modern Indian political evaluation.Subscribe for weekly political analysis breakdowns, and comment below on which policy area you want us to cover next.00:00- 12 Years of BJP: Progress or Propaganda5:21 - Opening speech: BJP Spokesperson9:10 - Opening Speech: Opposition Spokesperson12:05 - Is the BJP open to criticism?15:08 - Is the Police Brutality Real or not?29:42 - Is India failing its students?29:46 - Is India Failing its Students?36:09 - Is India Facing a Job Crisis!37:18 - Is Government Education System Failing?42:57 - Can India become Rich before it becomes Old45:30 - Is "Make in India" Failing47:02 - Do Global Supply Shock Justify Manufacturing Slowdown53:14 - Is Indian infrastructure getting worse or better?01:05:13 - India's Shocking doctor shortage crisis01:12:00 - Why is the trade decifict increasing?01:16:28 - Closing speech

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

Curious about the future of radiology economics? Richard E. Heller III, MD, MBA speaks with co-hosts Sherry S. Wang, MBBS, and Surbhi Raichandani, MD, to discuss radiology economics, from the basics to the niche and what is up ahead. Listen to their discussion in episode 2 of Difficult Conversations, an AJR Podcast Series. Full article: https://www.ajronline.org/doi/10.2214/AJR.26.35690 *Key Takeaways The Efficiency Fallacy: CMS recently implemented a 2.5% efficiency reduction to work relative value units, assuming that technology makes reading scans faster. However, modern multiplanar CTs contain thousands of images which can slow down down interpretation times. The No Surprises Act and Ghost Rates: While designed to protect patients from unexpected out-of-network bills, poor implementation allows insurers to use "ghost rates," which are contracted rates for never-billed services, to artificially lower the Qualifying Payment Amount and force rate reductions on practices. Advocacy is Essential: Radiologists serve as the nexus of the hospital. If the specialty does not demonstrate its downstream value, such as avoiding unnecessary surgeries and shortening hospital stays, business-minded policymakers will continue to treat it as a high-cost expense center to be cut. *Chapters  0:00 - Welcome 1:12 - Future Outlook For Radiology 2:27 -  How Radiologists Generate Revenue 3:09 - RVUs Conversion Factor Basics 4:30 - MIPS And Payment Adjustments 5:59 - Revenue Versus Paycheck 7:22 - Medicare Fee Schedule Trends 8:53 - Efficiency Adjustment Debate 12:50 - How CMS Sets The Rules 14:24 - Comment Letters And Advocacy 17:16 - Medicare As System Benchmark 19:09 - Commercial Insurer Headaches 21:21 - Steerage And Pediatric Risks 22:57 - No Surprises Act Explained 27:59 - Arbitration And Implementation Issues 29:10 - Radiology as Nexus 30:16 - Proving Downstream Value 31:34 - Total Value Equation 33:44 - RVUs and Complexity 36:53 - Fixing Incentives 46:04 - AI as Capacity Booster 49:01 - Will AI Cut Pay 50:12 - Teleradiology Done Right 54:30 - Radiology in 10 Years 57:53 - Optimism and Call to Action Follow AJR on Social Media LinkedIn: https://www.linkedin.com/showcase/ajr-radiology/ YouTube: https://www.youtube.com/channel/UCfFAYezkLMxJGMgIJLN0Dpg Instagram: https://www.instagram.com/ajr_radiology/ TikTok: https://www.tiktok.com/@ajr_radiology X: https://x.com/AJR_Radiology BlueSky: https://bsky.app/profile/ajrradiology.bsky.social Threads: https://www.threads.com/@ajr_radiology *These sections were generated using artificial intelligence (Descript and Google Gemini) and then reviewed for accuracy.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027.Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027.Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027.Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027.Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027.Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027.Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027.Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027.Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027.Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SKY865. CME/AAPA credit will be available until July 28, 2027.Moving MEK Inhibitor Therapy FORWARD in NF1: A Neuro-Oncology FOrum on Real-World Application of Recent Data for Improving Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks, a healthcare company of Merck KGaA, Darmstadt, Germany.Disclosure information is available at the beginning of the video presentation.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD (academic clinical lecturer in rheumatology, University of Leeds), and Rihards Buss, MD (consultant rheumatologist, Freeman Hospital, Newcastle), record a post-EULAR 2026 debrief, working through the abstracts each identified as the meeting's most consequential. The conversation spans cellular therapies in autoimmune disease, proteomic biomarkers for treatment selection in RA, a landmark head-to-head trial in psoriatic arthritis, evolving classification criteria for axial spondyloarthritis, and the first phase III randomized controlled trial of a JAK inhibitor in polymyalgia rheumatica.Studies featured in this episode include: AB-101 Allogeneic NK Cell Therapy in Rheumatologic Diseases (LB0003)  CARLYSLE: Obe-Cel CAR T in Severe Refractory SLE (OP0341) Ex Vivo Proteomic Signatures of JAK and TNF Inhibitors Predict Treatment Response in RA (OP048) BE BOLD: Bimekizumab vs Risankizumab in PsA (LB0001) 2025 ASAS-SPARTAN Revised AxSpA Classification Criteria (OP0236, OP0239, POS0190, POS1341) JAK-SPARE: Baricitinib in Early Polymyalgia Rheumatica (LB0005) Click here to read more and watch the full video at RheumatologyLive.

Testosterone for women: what the evidence actually shows vs. what social media is selling you. Testosterone has become the hormone every midlife woman is told she is missing: the third hormone lost at menopause, the fix for brain fog, low energy, stubborn weight, and thinning muscle. The science tells a different and more reassuring story. In this episode, Dr. Ayesha Sherzai sits down with Professor Susan Davis, MBBS, FRACP, PhD, the clinician-researcher and academic endocrinologist who gathered much of the data and helped write the global guidelines, to separate what the research supports from what is simply being sold. Your Brain On... Testosterone [Season 7, Episode 7] Get our FREE NEURO Plan Brain Health Playbook: https://thebraindocs.com/playbook In this episode: Why testosterone does not crash at menopause the way estrogen does, and what actually changes across a woman's life What the research shows about testosterone and memory, brain fog, and dementia risk The real story on testosterone for muscle, bone, and anti-aging claims Why women tend to gain a little weight on testosterone rather than lose it The one use with genuine evidence behind it: low sexual desire after menopause that causes real distress Why more is not better, and what high-dose testosterone actually does What is really inside compounded creams, injections, and testosterone pellets sold at med spas Why routine testosterone blood testing generates bills and anxiety rather than answers Why there is no such thing as testosterone deficiency in women How to tell an evidence-based clinician from a sales pitch What genuinely protects a woman's aging brain, and why connection matters more than any hormone Professor Susan Davis is a consulting endocrinologist at Monash University in Melbourne, where she directs a leading women's health research program. She has studied testosterone in women since the 1990s and is the lead author of the Global Consensus Position Statement on the Use of Testosterone Therapy for Women, endorsed by the International Menopause Society, The Endocrine Society, and menopause and obstetric societies around the world. References: Does testosterone crash at menopause? Wang Y, Islam RM, Bond M, Davis SR. Testosterone and pre-androgens by age and menopausal stage at midlife: findings from a cross-sectional study. EBioMedicine. 2025;121:105972. PMID: 41106025. Davis SR, Bell RJ, Robinson PJ, et al. Testosterone and estrone increase from the age of 70 years: findings from the Sex Hormones in Older Women Study. J Clin Endocrinol Metab. 2019;104(12):6291–6300. PMID: 31408149. Islam RM, Bell RJ, Handelsman DJ, Robinson PJ, Wolfe R, Davis SR. Longitudinal changes over three years in sex steroid hormone levels in women aged 70 years and over. Clin Endocrinol (Oxf). 2021;94(3):443–448. PMID: 33351205. Does testosterone improve memory or protect against dementia? Sultana F, Davis SR, Wolfe RS, McNeil JJ, Islam RM. Associations between blood sex hormones, cognitive decline and incident dementia in community-dwelling older Australian women: a prospective cohort study. Climacteric. 2025;28(4):446–455. PMID: 40085743. Sultana F, Islam RM, Davis SR. Associations between declining testosterone concentrations and cognitive performance in community-dwelling older Australian women: a prospective cohort study. Climacteric. 2026;29(1):46–52. What does testosterone therapy actually do? Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766. PMID: 31353194. What do the global guidelines say? Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666. PMID: 31498871. Can a blood test diagnose low testosterone? Wang Y, Islam RM, Hodge A, Handelsman DJ, Karim MN, Bond M, Davis SR. Associations between testosterone and pre-androgens and sexual function: findings from the Australian Women's Midlife Years Study. Fertility and Sterility. 2026. Get our FREE NEURO Plan Brain Health Playbook: https://thebraindocs.com/playbook Hosted by Drs. Ayesha & Dean Sherzai. Subscribe to The Synapse (free weekly newsletter): https://thebraindocs.com/newsletter  Follow @TheBrainDocs on Instagram

Send us Fan MailInside Dental College: The Truth Every NEET Aspirant Must KnowIs Dentistry really a good career option after NEET?In this insightful episode of The Kapeel Gupta Career PodShow, we sit down with Dr. Aakansha Mishra, a BDS graduate and MDS (Periodontology) scholar, to uncover the real journey of becoming a dentist. From dental college life and clinical training to specialization, career opportunities, challenges, and the future of dentistry, this conversation offers valuable insights for every NEET aspirant, student, and parent. If you are confused between MBBS and BDS, wondering whether dentistry is the right choice, or simply want to understand the realities of the profession, this episode is for you.

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Prashanthan Sanders, MBBS, PhD, FHRS, about the journal article, Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm. Together, they discuss the study findings and explore the relationship between atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy who are in sinus rhythm.   Learning Objectives: Review the key findings of the study examining atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy and sinus rhythm. Discuss the association between atrial mechanical contraction and cerebrovascular risk in this patient population. Explore the potential clinical implications of assessing atrial mechanical function in patients with transthyretin amyloid cardiomyopathy.   Host: Michael S. Lloyd, MD, FHRS   Guests: Tina Baykaner, MD, MPH Prashanthan Sanders, MBBS, PhD, FHRS   Disclosures: M. Lloyd Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other   T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   P. Sanders Honoraria/Speaking/Consulting Fee: Boston Scientific, Abbott Medical Other Financial Relationships: Medtronic PLC, Pacemate, CathRx Research: Abbott, Becton Dickinson, Calyan Technologies, Ceryx Medical, Biosense Webster, CathRx, HelloAlfred, Medtronic, Inc., Abbott Medical

Gout Journal Club will examine two influential publications: 1. "Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients with Gout" (Cipolletta et al., JAMA Internal Medicine, 2026) and 2. "Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease"(Wang et al., JAMA Internal Medicine, 2025). Together, these studies provide new evidence supporting treat-to-target urate-lowering strategies and their potential impact on cardiovascular and renal outcomes. Panelists: Abhishek Abhishek, MD, PhD, MBBS, FRCP Zeqin Wen, MD Jie Wei, PhD Jack Cush, MD (moderator) Beyond reviewing the evidence, our expert panel will tackle the practical questions rheumatologists face every day.

As radiologists, we work in dark rooms, but some shadows have nothing to do with the monitors. Cohosts Sherry S. Wang, MBBS, and Surbhi Raichandani, MD, illuminate bullying, gossip, and incivility in radiology and the small brave moves that build healthier cultures. Listen to their discussion in episode 1 of Difficult Conversations, an AJR Podcast Series.

Radiologists are trained to catch every detail, yet as a profession, it's easy to overlook the human struggles happening right in the reading room. Join Surbhi Raichandani, MD and Sherry Wang, MBBS as they introduce a new AJR Podcast Series dedicated to discussions around bullying, power dynamics, financial pressures, and what it takes to survive in this field. There are no scripts and no safe answers, just real stories from the people who have lived them.

Join hosts Nidhi Madan, MD; Prashant Nagpal, MD, FSCCT; Jill Jacobs, MD, MS-HQSM, FSCCT and Cristina Fuss, MD, PhD, FSCCT as they take a deep dive into featured articles in the March – April 2026 issue of the Journal of Cardiovascular Computed Tomography (JCCT). Our hosts chat with Gemma Figtree, MD; Michael Gray, MPH and Abdul Rahman Ihdayhid, MBBS, PhD, FRACP.This episode will explore:Disproportionate Atherosclerotic Burden in the Left Anterior Descending Coronary Artery in Participants without Standard Modifiable Cardiovascular Risk Factors The Multi-Ethnic Study of Atherosclerosis (MESA) Feasibility and Utility of Anatomical and Physiological Evaluation of Coronary Artery Disease with Cardiac CT in Severe Aortic Stenosis (FUTURE-AS Registry) Support the show

This episode features co-host Marc Larochelle's interviews with five authors of abstracts presented at the Together for Hope 2026 annual conference. Behind the Evidence is the addiction medicine podcast of the Grayken Center for Addiction at Boston Medical Center, and a project of the Center's free bimonthly newsletter Alcohol, Other Drugs, and Health: Current Evidence (AODH). 1) “From Single-Substance Alerts to Mixture Monitoring: Network Analysis of Expected-Opioid Samples from a Syringe Service Program-Based Drug Checking Initiative.”- Kyle Harrington, Tapestry Health2) “The pathways and impacts of permanent housing: Guest and provider insights on the transition from low-threshold shelters (LTS) to permanent housing.”- Jeffrey Desmarais, MA: Institute for Community Health & Shivangi Singh, MBBS, MPH: Boston Public Health Commission3) “One Year of the Rhode Island Overdose Prevention Center: Service Utilization and Peer‑Led Overdose Response Outcomes.”- Miriam Harris, MD, MSc: Boston University Chobanian & Avedisian School of Medicine, Project Weber/Renew: Rhode Island's Center for Harm Reduction and Recovery Services4) “Interest in long-acting HIV pre-exposure prophylaxis (PrEP) and medications for opioid use disorder among persons who inject drugs: A cross-sectional study.”- Sarah Miller, Boston Medical Center5) “Evaluation of a Pilot Community-Based Treatment Program for Youth with Frequent Substance Use and Symptoms of Psychosis.”- Morgan Ellis, MHS; Boston Medical Center Hosts: Honora L. Englander, MD and Marc R. Larochelle, MDProduction: Raquel Silveira, MBAEditing: Casy Calver, PhDMusic and cover art: Mary Tomanovich, MAMiriam Komaromy, MD is the Executive Director of the Grayken Center for Addiction, and co-Editor-in-Chief of AODH, together with David Fiellin, MDLearn more about AODH and subscribe for free at www.aodhealth.org“Behind the Evidence” is supported by the Grayken Center for Addiction at Boston Medical Center. It is intended for educational purposes only, and should not be considered medical advice. The views expressed here are our own, and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

In this episode of Joint Ventures, host Rihards Buss, MD, consultant rheumatologist, Freeman Hospital, Newcastle, sits down with Sarah Dyball, MBBS, PhD, academic clinical lecturer, Centre for Musculoskeletal Research, University of Manchester, and Kate Harnden, MBChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London.Click here to watch the episode.

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Muscle-Invasive and Muscle-Invasive Urothelial Bladder Cancer | Faculty Presentation 1: Non-Muscle-Invasive Bladder Cancer — Ashish M Kamat, MD, MBBS CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Muscle-Invasive and Muscle-Invasive Urothelial Bladder Cancer | Faculty Presentation 2: Muscle-Invasive Bladder Cancer — Thomas Powles, MBBS, MRCP, MD CME information and select publications

Sleep, Airway and Mouth Breathing: An ENT's Guide for Dentists Could a “normal” sleep study still be missing your patient's airway problem? Why do women and children with real symptoms keep scoring “mild”? Should a mouth-breathing child see a myofunctional therapist — or an ENT first? And which four questions screen a child for sleep problems in under a minute? The roof of the mouth is the floor of the nose — so ENT and dentistry should be in constant dialogue. In practice, they rarely are. In this one, Dr David McIntosh — an Australian ear, nose and throat surgeon with a deep niche in sleep-disordered breathing — makes the case for why that has to change, and gives dentists practical ways to screen and refer. He is direct, analogy-rich and doesn't mince words; expect a few positions that cut against the grain of how sleep apnoea is usually handled. https://youtu.be/QVEc0ocxTCc Watch PDP272 on YouTube Protrusive Dental Pearl: When the Numbers Mislead Dentists love data — the AHI, the cut-offs (over 5 is mild, over 30 is severe). But take those numbers with a pinch of salt: the thresholds are arbitrary, and a single score tells you nothing about why a patient has the problem. They don't account for individual variability — especially in women and children, where a mild score can sit right alongside significant symptoms. Read the number with the anatomy and the phenotype — the clinical signs and the airway assessment — never instead of them. What You'll Take From This Episode This conversation reframes sleep-disordered breathing from a number on a report into something you can localise and refer.  A sleep study tells you IF, not WHY — sleep-disordered breathing is the whole spectrum; a normal study doesn't mean normal breathing. Phenotyping the airway — map the individual anatomical causes instead of trusting a single score. Why women get missed — the gender bias built into standard adult screening tools, and what to ask instead. The four-question filter for children — snore, mouth breathe, stop breathing, wake up tired: any ‘yes' means refer. Treat the cause before the function — why myofunctional therapy comes after the obstruction is cleared, not before, and how expansion and surgery are matched to the anatomy. Highlights of This Episode 00:00  Teaser 01:00  Why ENT and Dentistry Should Be Talking 02:51  Protrusive Dental Pearl: When Sleep Data Misleads You 03:46  Meet the ENT Who Works With Dentists 06:00  Sleep Physician, ENT or Dentist: Who Should Lead? 07:26  Why Children and Adults Are Completely Different 08:58  Sleep-Disordered Breathing Is Not the Same as Sleep Apnoea 09:39  Why a Normal Sleep Study Doesn't Mean Normal Breathing 10:01  Same AHI, Different Cause: A Tale of Two Patients 12:54  Why One Night's Sleep Study Isn't Enough 13:44  Where the AHI Cut-Off Numbers Really Came From 15:27  CPAP Explained: A Bridge, Not a Cure 18:27  When Snoring Hides Something Serious 19:10  What Phenotyping the Airway Actually Means 20:27  Splint, CPAP, or Both? 21:33  Why a CBCT Can Miss a Deviated Septum 25:32  Is STOP-Bang Enough to Screen for Sleep Apnoea? 26:06  Why the Epworth Sleepiness Scale Is a Blunt Tool 26:50  Why STOP-Bang Is Biased Against Women 31:17  Sleep Apnoea in Women: Mild on Paper, Severe in Life 32:05  Midroll 36:56  The Triad: Airway, TMD and Orthodontics 37:12  The Three Most Common Causes of Night-Time Grinding 39:41  The Four Questions That Screen a Child for Sleep Problems 41:03  Tired vs Not Tired: The Sign That Changes Everything 43:36  Should You Refer to Myofunctional Therapy Before an ENT? 45:58  The Hidden Dangers of Forcing Nasal Breathing 52:28  Maxillary Expansion vs Surgery: Which One Fixes It? 54:51  How Dentists Can Assess Adenoids 56:25  Save the Child First: The Drowning Analogy 57:56  Where Dentistry and ENT Go From Here 1:00:05  Outro – New-Look Premium Notes & CPD Outro From the Guest Dr David McIntosh is an ear, nose and throat surgeon (MBBS, FRACS, PhD) with a special interest in sleep-disordered breathing and airway obstruction. A self-described compulsive educator, he is the author of several books on Amazon — including dENTal health, on the connection between ENT and dental disease, and Snored to Death, on the lesser-recognised causes of obstructive sleep apnoea in adults. References & Further Reading Sources discussed in this episode: Chervin RD, Hedger K, Dillon JE, Pituch KJ. Pediatric sleep questionnaire (PSQ): validity and reliability of scales for sleep-disordered breathing, snoring, sleepiness, and behavioral problems. Sleep Medicine, 2000;1(1):21–32. The 22-item PSQ; a score above 0.33 suggests sleep-disordered breathing. Loved This Episode? Try Next Airway Dentistry with Jeff Rouse – PDP229 Listen, Subscribe, Earn CPD This episode is eligible for 1 CE credit via the quiz on Protrusive Guidance. This episode meets GDC Outcomes C AGD Subject Code: 730 – Oral Medicine, Oral Diagnosis, Oral Pathology (Sleep medicine) #PDPMainEpisodes #OralSurgeryandOralMedicine Aim & Learning Outcomes Aim: To help dental practitioners recognise sleep-disordered breathing across the whole airway, screen adults and children appropriately, and refer at the right time and to the right clinician. Learning Outcomes — by the end of this episode, dentists will be able to: Differentiate sleep-disordered breathing from obstructive sleep apnoea, and explain why a normal sleep study does not exclude clinically significant breathing problems. Apply a structured screening approach for adults and children, including recognising why standard adult tools under-detect sleep-disordered breathing in women and children. Evaluate when to refer for specialist airway assessment, and articulate why addressing anatomical obstruction should precede functional (myofunctional) therapy.

Sleep, Airway and Mouth Breathing: An ENT's Guide for Dentists Could a “normal” sleep study still be missing your patient's airway problem? Why do women and children with real symptoms keep scoring “mild”? Should a mouth-breathing child see a myofunctional therapist — or an ENT first? And which four questions screen a child for sleep problems in under a minute? The roof of the mouth is the floor of the nose — so ENT and dentistry should be in constant dialogue. In practice, they rarely are. In this one, Dr David McIntosh — an Australian ear, nose and throat surgeon with a deep niche in sleep-disordered breathing — makes the case for why that has to change, and gives dentists practical ways to screen and refer. He is direct, analogy-rich and doesn't mince words; expect a few positions that cut against the grain of how sleep apnoea is usually handled. https://youtu.be/QVEc0ocxTCc Watch PDP272 on YouTube Protrusive Dental Pearl: When the Numbers Mislead Dentists love data — the AHI, the cut-offs (over 5 is mild, over 30 is severe). But take those numbers with a pinch of salt: the thresholds are arbitrary, and a single score tells you nothing about why a patient has the problem. They don't account for individual variability — especially in women and children, where a mild score can sit right alongside significant symptoms. Read the number with the anatomy and the phenotype — the clinical signs and the airway assessment — never instead of them. What You'll Take From This Episode This conversation reframes sleep-disordered breathing from a number on a report into something you can localise and refer.  A sleep study tells you IF, not WHY — sleep-disordered breathing is the whole spectrum; a normal study doesn't mean normal breathing. Phenotyping the airway — map the individual anatomical causes instead of trusting a single score. Why women get missed — the gender bias built into standard adult screening tools, and what to ask instead. The four-question filter for children — snore, mouth breathe, stop breathing, wake up tired: any ‘yes' means refer. Treat the cause before the function — why myofunctional therapy comes after the obstruction is cleared, not before, and how expansion and surgery are matched to the anatomy. Highlights of This Episode 00:00  Teaser 01:00  Why ENT and Dentistry Should Be Talking 02:51  Protrusive Dental Pearl: When Sleep Data Misleads You 03:46  Meet the ENT Who Works With Dentists 06:00  Sleep Physician, ENT or Dentist: Who Should Lead? 07:26  Why Children and Adults Are Completely Different 08:58  Sleep-Disordered Breathing Is Not the Same as Sleep Apnoea 09:39  Why a Normal Sleep Study Doesn't Mean Normal Breathing 10:01  Same AHI, Different Cause: A Tale of Two Patients 12:54  Why One Night's Sleep Study Isn't Enough 13:44  Where the AHI Cut-Off Numbers Really Came From 15:27  CPAP Explained: A Bridge, Not a Cure 18:27  When Snoring Hides Something Serious 19:10  What Phenotyping the Airway Actually Means 20:27  Splint, CPAP, or Both? 21:33  Why a CBCT Can Miss a Deviated Septum 25:32  Is STOP-Bang Enough to Screen for Sleep Apnoea? 26:06  Why the Epworth Sleepiness Scale Is a Blunt Tool 26:50  Why STOP-Bang Is Biased Against Women 31:17  Sleep Apnoea in Women: Mild on Paper, Severe in Life 32:05  Midroll 36:56  The Triad: Airway, TMD and Orthodontics 37:12  The Three Most Common Causes of Night-Time Grinding 39:41  The Four Questions That Screen a Child for Sleep Problems 41:03  Tired vs Not Tired: The Sign That Changes Everything 43:36  Should You Refer to Myofunctional Therapy Before an ENT? 45:58  The Hidden Dangers of Forcing Nasal Breathing 52:28  Maxillary Expansion vs Surgery: Which One Fixes It? 54:51  How Dentists Can Assess Adenoids 56:25  Save the Child First: The Drowning Analogy 57:56  Where Dentistry and ENT Go From Here 1:00:05  Outro – New-Look Premium Notes & CPD Outro From the Guest Dr David McIntosh is an ear, nose and throat surgeon (MBBS, FRACS, PhD) with a special interest in sleep-disordered breathing and airway obstruction. A self-described compulsive educator, he is the author of several books on Amazon — including dENTal health, on the connection between ENT and dental disease, and Snored to Death, on the lesser-recognised causes of obstructive sleep apnoea in adults. References & Further Reading Sources discussed in this episode: Chervin RD, Hedger K, Dillon JE, Pituch KJ. Pediatric sleep questionnaire (PSQ): validity and reliability of scales for sleep-disordered breathing, snoring, sleepiness, and behavioral problems. Sleep Medicine, 2000;1(1):21–32. The 22-item PSQ; a score above 0.33 suggests sleep-disordered breathing. Loved This Episode? Try Next Airway Dentistry with Jeff Rouse – PDP229 Listen, Subscribe, Earn CPD This episode is eligible for 1 CE credit via the quiz on Protrusive Guidance. This episode meets GDC Outcomes C AGD Subject Code: 730 – Oral Medicine, Oral Diagnosis, Oral Pathology (Sleep medicine) #PDPMainEpisodes #OralSurgeryandOralMedicine Aim & Learning Outcomes Aim: To help dental practitioners recognise sleep-disordered breathing across the whole airway, screen adults and children appropriately, and refer at the right time and to the right clinician. Learning Outcomes — by the end of this episode, dentists will be able to: Differentiate sleep-disordered breathing from obstructive sleep apnoea, and explain why a normal sleep study does not exclude clinically significant breathing problems. Apply a structured screening approach for adults and children, including recognising why standard adult tools under-detect sleep-disordered breathing in women and children. Evaluate when to refer for specialist airway assessment, and articulate why addressing anatomical obstruction should precede functional (myofunctional) therapy.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology, University of Leeds, was joined at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London by Laurence Duquenne, MD, a rheumatology researcher, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, an investigator on one of the meeting's standout studies to examine whether baseline naïve CD4+ T cell frequency can identify which newly diagnosed patients with rheumatoid arthritis (RA) are unlikely to respond to methotrexate monotherapy, and whether adding a biologic at the outset can close that gap.Click here to watch the episode.

The therapeutic framework for systemic sclerosis is undergoing a fundamental reorientation, moving away from managing visible fibrotic sequelae toward targeting the autoantibody-driven mechanisms believed to initiate and propagate disease.On a recent episode of Joint Ventures recorded live at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London, host Jack Arnold, MBBS, PhD, of the University of Leeds, spoke with Vishal Kakkar, MD, also of the University of Leeds and a specialist in scleroderma, about the most consequential data emerging from the congress.Click here to watch the episode.

Sepsis is a global health emergency, with nearly half of all septic patients being children. In this episode of the Society of Critical Care Medicine (SCCM) Podcast, Samantha Gambles Farr, MSN, NP-C, CCRN, RNFA, speaks with Niranjan Kissoon, MD, MBBS, FRCP(C), FACPE, MCCM, about his Thought Leader presentation at the 2026 Critical Care Congress, Making Sepsis the Next Success Story in Global Health. The panel also discusses how access and equity play a part in how sepsis is treated. From a global perspective, Dr. Kissoon emphasizes that the most important thing is advocacy and prevention from a governmental level by creating national action plans, making sure the healthcare system is resilient, and utilizing technology and innovation to create better ways of providing care; and from a societal level by educating patients and families about nutrition, hygiene, vaccinations, and seeking care early. Niranjan Kissoon, MD, MBBS, FRCP(C), FACPE, MCCM, is a professor in the Department of Pediatrics (Pediatrics and Surgery, Emergency Medicine) at the University of British Columbia in Vancouver, British Columbia, Canada. He is the past president of the World Federation of Pediatric Critical and Intensive Care Societies and currently serves as president of the Global Sepsis Alliance. He is cochair of the pediatric Surviving Sepsis Campaign, vice president of the Canadian Sepsis Foundation, and chair of World Sepsis Day and the International Pediatric Sepsis Initiative. He also serves on the Sepsis Alliance USA and the African Sepsis Alliance advisory boards and is also a founding member of the Caribbean Sepsis Alliance.